Latest Hotspot

IDeate-Lung01 Phase 2 Trial: Promising Response Rates with Ifinatamab Deruxtecan in Advanced Small Cell Lung Cancer

11 September 2024
3 min read

An interim analysis of the dose-optimization segment of the current IDeate-Lung01 phase 2 trial revealed that ifinatamab deruxtecan (I-DXd) remains to show promising objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). These findings were highlighted today during a press conference and will be shared in an oral presentation (OA04.03) on Sunday at the 2024 World Conference on Lung Cancer (#WCLC24), organized by the International Association for the Study of Lung Cancer.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序

描述已自动生成

Ifinatamab deruxtecan is an antibody drug conjugate (ADC) specifically designed as a potential first-in-class treatment targeting B7-H3. This ADC was discovered by Daiichi Sankyo (TSE: 4568) and is under joint development by Daiichi Sankyo and Merck (NYSE: MRK), identified as MSD outside the United States and Canada.

Small cell lung cancer (SCLC) ranks as the second most prevalent form of lung cancer, accounting for around 15% of lung cancer cases. SCLC is characterized by its aggressive nature and rapid progression to a metastatic stage, where the five-year survival rate plummets to only 3%. Approximately 65% of SCLC tumors exhibit moderate to high levels of B7-H3 protein, a marker linked to disease advancement and poor prognosis.

"Many patients undergoing treatment for small cell lung cancer face swift disease progression, highlighting the significant unmet need in advanced-stage care," stated Charles M. Rudin, MD, PhD, Deputy Director of Memorial Sloan Kettering Cancer Center and Co-Director of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research. "Initial data from the first segment of the IDeate-Lung01 trial indicate that ifinatamab deruxtecan might play a crucial role in managing patients with previously treated extensive-stage small cell lung cancer, meriting further investigation."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of September 11, 2024, there are 4 investigational drugs for the CD276 x TOP1 target, including 13 indications, 10 R&D institutions involved, with related clinical trials reaching 22, and as many as 119 patents.

Ifinatamab deruxtecan is an antibody drug conjugate (ADC) that targets CD276 and TOP1. It is being developed for the treatment of a wide range of therapeutic areas, including neoplasms, respiratory diseases, digestive system disorders, urogenital diseases, and other diseases. The drug is currently being investigated for the treatment of small cell lung cancer, solid tumor, non-small cell lung cancer, ES-SCLC, colorectal cancer, advanced cancer, neuroendocrine carcinoma, advanced malignant solid neoplasm, castration-resistant prostatic cancer, and esophageal squamous cell carcinoma.

图形用户界面, 文本, 应用程序

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 11
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 11
11 September 2024
Sep 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
Latest Hotspot
3 min read
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
10 September 2024
GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).
Read →
Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application
Hot Spotlight
6 min read
Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application
10 September 2024
Competing in the $40 Billion Alopecia Areata Market: Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application.
Read →
Ventyx Biosciences Begins Phase 2a Trial Dosing of VTX3232 for Early Parkinson’s Disease
Latest Hotspot
3 min read
Ventyx Biosciences Begins Phase 2a Trial Dosing of VTX3232 for Early Parkinson’s Disease
10 September 2024
Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.